Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Fleming, Gini F.

Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index

- Desmedt, Christine, Fornili, Marco, Sotiriou, Christos, Piccart, Martine, Biganzoli, Elia, Clatot, Florian, Demicheli, Romano, De Bortoli, Davido, Di Leo, Angelo, Viale, Giuseppe, de Azambuja, Evandro, Crown, John, Francis, Prudence A.

Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

- Ribi, Karin, Luo, Weixiu, Walley, Barbara A., Burstein, Harold J., Chirgwin, Jacquie, Ansari, Rafat H., Salim, Muhammed, van der Westhuizen, Andre, Abdi, Ehtesham, Francis, Prudence A., Chia, Stephen, Harvey, Vernon J., Giobbie-Hurder, Anita, Fleming, Gini F., Pagani, Olivia, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

- Ribi, Karin, Luo, Weixiu, Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Colleoni, Marco, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L.

Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials

- Fleming, Gini F., Saha, Poornima, Burstein, Harold J., Parmar, Vani, Torres, Roberto, Stewart, Josephine, Bellet, Meritxell, Perello, Antonia, Dane, Faysal, Moreira, Antonio, Vorobiof, Daniel, Nottage, Michelle, Regan, Meredith M., Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Colleoni, Marco, Pagani, Olivia, Francis, Prudence A., Walley, Barbara A., Ribi, Karin, Bernhard, Jurg, Luo, Weixiu, Gomez, Henry L.

Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

- Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

- Pagani, Olivia, Walley, Barbara A., Stearns, Vered, Bonnefoi, Hervé R., Martino, Silvana, Geyer, Charles E., Chini, Claudio, Puglisi, Fabio, Spazzapan, Simon, Ruhstaller, Thomas, Winer, Eric P., Ruepp, Barbara, Fleming, Gini F., Loi, Sherene, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, Francis, Prudence A., SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation),, Colleoni, Marco, Láng, István, Gomez, Henry L., Tondini, Carlo, Burstein, Harold J., Goetz, Matthew P., Ciruelos, Eva M.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

- Moore, Halle C. F., Unger, Joseph M., Partridge, Anne H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M, Forbe, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L. Jr, Gelber, Richard D., Hortobagyi, Gabriel N, Albain, Kathy S., Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

- Fernández-Cuesta, Lynnette, Oakman, Catherine, Larsimont, Denis, Francis, Prudence A., Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali, Falagan-Lotsch, Patricia, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M. Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia

Are SOFT and TEXT results practice changing and how?

- Pagani, Olivia, Regan, Meredith M., Francis, Prudence A.

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

- Francis, Prudence A., Pagani, Olivia, Bennefoi, Herve R., Bellet, Meritxell, Martino, Silvana, Geyer, Jr., Charles E., Goetz, Matthew P., Stearns, Vered, Pinotti, Graziella, Puglisi, Fabio, Spazzapan, Simon, Climent, Miguel A., Fleming, Gini F., Pavesi, Lorenzo, Ruhstaller, Thomas, Davidson, Nancy E., Coleman, Robert, Debled, Marc, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Maibach, Rudolf, Rabaglio-Porretti, Manuela, Walley, Barbara A., Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Regan, Meredith M., Colleoni, Marco, Lang, Istvan, Gomez, Henry L., Tondini, Carlo, Ciruelos, Eva, Burstein, Harold J.

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Colleoni, Marco, Gelber, Richard D., Francis, Prudence A., International Breast Cancer Study Group (IBCSG),, SOFT Investigators,, TEXT Investigators,, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirsch, Aron

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Martino, Silvana, Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Fleming, Gini F., Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Lang, István Láng, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Hervé R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

- Francis, Prudence A., Fleming, Gini F., Burstein, Harold J., Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Ingle, James N., Coleman, Robert E., Müller, Bettina, Le Du, Fanny, Loibl, Sibylle, Winer, Eric P., Láng, István, Ruepp, Barbara, Loi, S, Colleoni, M, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation),, Ciruelos, Eva M., Bonnefoi, Hervé R., Bellet, Meritxell, Bernardo, Antonio, Climent, Miguel A., Martino, Silvana, Bermejo, Begoña

Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration

- Francis, Prudence A.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

- Sonnenblick, Amir, Salgado, Roberto, Crown, John, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, de Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine, Bromberg, Jacqueline, Sotirou, Christos, Brohee, Sylvain, Zahavi, Tamar, Peretz, Tamar, van den Eynden, Gert, Rouas, Ghizlaine, Salmon, Asher, Francis, Prudence A., Di Leo, Angelo

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

- Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil

Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

- Sonnenblick, Amir, Francis, Prudence A., Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Barnadas, Agusti, Cortes-Funes, Hernan, Piccart, Martine, Crown, John, Azim Jr, Hatem A., de Azambuja, Evandro, Nordenskjold, Bo, Gutierez, Jorge, Quinaux, Emmanuel, Mastropasqua, Mauro G., Ameye, Lieveke, Anderson, Michael

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

- Moore, Halle C. F., Unger, Joseph M., Partridge, Ann H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M., Forbes, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L., Gelber, Richard D., Hortobagyi, Gabriel N., Albain, Kathy S., Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.